January 19, 2023
WILMINGTON, DE – After a week-long bench trial held in Delaware in May, Judge Richard Andrews ruled in Exelixis’ favor this past Thursday, rejecting MSN’s challenge to the cabozantinib compound patent (U.S. 7,579,473).
Impact Trial’s team members working with the WilmerHale team were Thomas S.Y. Lee, Addison Moyer, Alan Bui, Alison Von Dollen, CMI, Rebecca Lavernoich, Brian Lee, Jeff Woodbury, John Christopher, Mary Koger, Megan Bishop, Melissa Pomerantz, Nova Hayes, Ouliana Nikolaeva-Hir, and Stu Lucero.
Congratulations to the WilmerHale team, our Impact Trial members, and Exelixis!
The case is Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), in the U.S. District Court for the District of Delaware.